logo
China bans surgical treatment of Alzheimer's

China bans surgical treatment of Alzheimer's

Time of India4 days ago
Beijing: China has banned surgical treatment of Alzheimer's disease after it was performed in about 400 hospitals over four years, saying there is a lack of high-quality medical evidence to support its safety and effectiveness.
The procedure, known as
lymphatic-venous anastomosis
(LVA), involves connecting the patient's lymph vessels to veins near the neck to speed up the flow and drainage of lymph fluid. The aim is to boost the removal of harmful brain proteins and slow the disease's progression.
The National Health Commission said it has recently learned that some medical institutions are conducting lymphaticovenous anastomosis, also known as LVA surgery, on patients diagnosed with Alzheimer's disease.
Following the commission's discovery, it conducted assessments on the procedure's safety and efficacy, the Commission said in a notice.
"Our evaluation concludes that there is a lack of evidence from preclinical studies in the use of LVA surgery for
Alzheimer's disease treatment
," it said, state-run China Daily reported on Friday.
"The procedure remains at an early stage of clinical research with its indications and contraindications yet to be clarified, and there is insufficient medical or health economic evidence attesting to its safety, efficacy and cost-effectiveness," the commission added.
Local health authorities are advised to instruct medical institutions to halt treating Alzheimer's disease with LVA surgery and guarantee proper follow-up care for affected patients.
"When sufficient preclinical evidence is collected, qualified medical institutions can carry out clinical studies under the full deliberation of ethics committees," it added.
The surgery has grown in popularity, particularly over the past year, since it was first performed in 2021 by a microsurgery expert from a private hospital in Hangzhou, in the eastern province of Zhejiang.
Based on publicly available information, an estimated 382 hospitals across almost all Chinese provinces had performed the procedure by the end of June, the Hong Kong-based South China Morning Post reported.
Alzheimer's disease - the leading cause of dementia - is a brain disorder that slowly destroys memory and thinking skills, and eventually the ability to carry out the simplest tasks.
When the surgery first came to public attention, some Chinese doctors promoted it enthusiastically on social media, claiming it was "effective for 60 to 80 per cent of patients", according to the Post report.
But it has also been met with scepticism, with some medical experts questioning its fundamental mechanism and long-term effectiveness.
Dr Fan Dongsheng, a professor in the neurology department at Peking University Third Hospital, warned that the scientific mechanism behind the treatment had not been well studied and was at present not convincing.
He told the Post that the reported improvements in patient symptoms were qualitative and not based on the accepted evaluation system.
Fan welcomed the government's decision to halt the treatment, calling it "apparently problematic" that many hospitals, even small ones, performed the surgery extensively without solid evidence and had charged patients for it.
Users on the Chinese social media platforms, however, expressed their anxiety that diagnosed family members would no longer be able to receive the treatment.
"If the patient's family agrees, I think it's worth trying because some patients are in a really serious condition and their families are exhausted and desperate," a person from northeastern Liaoning wrote.
One man said that his father, who was treated in March, had recovered well and could now recognise people and look after himself.
If surgery had the potential to improve patients' conditions, "most families would choose to give it a try", he told the Post. PTI
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Emcure enters distribution agreement with Sanofi for diabetes drugs
Emcure enters distribution agreement with Sanofi for diabetes drugs

Business Standard

time28 minutes ago

  • Business Standard

Emcure enters distribution agreement with Sanofi for diabetes drugs

Emcure to distribute and promote Sanofi's oral anti-diabetic brands Amaryl and Cetapin in India, expanding access amid rising prevalence of uncontrolled diabetes Emcure added that it will engage with healthcare professionals and expand the reach of these therapeutic solutions for patients across the country. Sanket Koul New Delhi Pune-based Emcure Pharmaceuticals on Wednesday announced an exclusive distribution and promotion agreement with Sanofi India (SIL) for its oral anti-diabetic (OAD) products in India. Under the agreement, SIL will continue to own and manufacture the brands across its plants in India and internationally, while Emcure will exclusively distribute and promote SIL's OAD range, which includes well-established brands such as Amaryl and Cetapin. There will be no employee transition from SIL to Emcure as part of this arrangement, the Pune-based drugmaker said in a regulatory filing to the exchanges. Emcure added that it will engage with healthcare professionals and expand the reach of these therapeutic solutions for patients across the country. 'With our strong distribution network in India, Sanofi's trusted oral anti-diabetic medicines will be available to more patients who need them,' he added. Over 100 million Indians are currently living with type 2 diabetes and its associated complications, according to a study by the Indian Council of Medical Research–INDIAB (India Diabetes). 'Of these, more than 60 per cent are living with uncontrolled blood sugar levels and are at higher risk of developing complications over time,' said Eric Mansion, general manager (pharma) for Southeast Asia and India at Sanofi. He added that with Emcure's wide and deeply penetrated presence across India, the company is confident of tapping the full growth potential of Amaryl and Cetapin. The announcement was made post market hours. On Wednesday, shares of Emcure Pharmaceuticals closed marginally higher by 0.22 per cent at Rs 1,363.85 apiece on the Bombay Stock Exchange (BSE).

Friends of Snakes Society completes 30 years rescuing reptiles in Telangana and Andhra Pradesh
Friends of Snakes Society completes 30 years rescuing reptiles in Telangana and Andhra Pradesh

The Hindu

time28 minutes ago

  • The Hindu

Friends of Snakes Society completes 30 years rescuing reptiles in Telangana and Andhra Pradesh

Hyderabad-based Friends of Snakes Society (FOS), whose members are actively involved in rescuing snakes in Telangana and Andhra Pradesh, completed 30 years on June 30. To commemorate the anniversary and in the lead-up to World Snake Day (July 16), it would launch a Snakebite Mitigation initiative to reduce snake bite deaths in the two Telugu States by half by 2030. A key component of the initiative is a dedicated website, which would be launched in a few days. It would feature information on a hospital locator tool for snake bite treatment; first aid protocols for snakebites; a 24/7 snake identification cell where people can submit photos online and region-specific information on venomous snake species and venomous snakes distribution map. 'In addition to the digital platform, FOS will conduct snake bite mitigation and management workshops at various levels, targeting local health workers, school teachers, panchayat leaders, and forest personnel,' said Avinash Visvanathan, general secretary of the Society. The focus will be on areas where incidence of snake bites is high. Mr. Avinash said that they would reach out to people in rural areas, communities and healthcare workers in Primary Health Centres in such regions.

Army successfully tests Akash Prime air defence system at 15,000 ft in Ladakh
Army successfully tests Akash Prime air defence system at 15,000 ft in Ladakh

India Today

timean hour ago

  • India Today

Army successfully tests Akash Prime air defence system at 15,000 ft in Ladakh

In a key boost to India's air defence capabilities, the Indian Army on Wednesday successfully conducted high-altitude trials of the indigenously developed Akash Prime surface-to-air missile system in tests were carried out at over 15,000 feet by the Army Air Defence in collaboration with senior officials from the Defence Research and Development Organisation (DRDO), who developed the officials said the missiles achieved two direct hits on fast-moving aerial targets in the rarified atmosphere, demonstrating the system's effectiveness in extreme Akash Prime will be inducted as part of the Army's third and fourth Akash regiments. The system had earlier proved its operational success during Operation Sindoor, where it helped counter aerial threats from Pakistan's military using Chinese jets and Turkish drones.- Ends

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store